



FIG. 1


1) Chondroitin sulfate/(GlcA-GalN)n




2) Dermatan sulfate/(IdoA/GlcA-GalN)n




3) Heparan sulfate/(GlcA/IdoA-GlcN)n




4) Heparin/(IdoA/GlcA-GlcN)n




5) Keratan sulfate/(Gal-GlcN)n



6) Hyaluronic acid/(GlcA-GlcN)n



7) Dextran sulfate/(Glc-Glc)n





APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 3

GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuAc $\alpha$ 2 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

1) Type I Core

Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuAc $\alpha$ 2 $\rightarrow$ 6Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuGc $\alpha$ 2 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 Fuc $\alpha$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

( $\rightarrow$ 8NeuGc $\alpha$ 2) $n$  $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 GalNAc $\beta$ 1 $\rightarrow$ 4GalNAc $\beta$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuGc $\alpha$ 2  
 2) Type II Core

NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

3) Type III Core

NeuAc $\alpha$ 2 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 Fuc $\alpha$ 1 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

4) Type IV Core

GlcNAc $\beta$ 1 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

5) Type V Core

Gal $\alpha$ 1 $\rightarrow$ 4Gal $\beta$ 1 $\rightarrow$ 4Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr  
 NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4GlcNAc $\beta$ 1 $\rightarrow$ 6GalNAc $\alpha$ 1 $\rightarrow$ 3GalNAc $\alpha$ 1 $\rightarrow$ Ser/Thr

FIG. 4




FIG. 5





FIG. 6



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 7





FIG. 8



- *E. coli*-Derived FGF-1a/with heparin
- *E. coli*-Derived FGF-1a/without heparin
- N-FGF-6/1a-IV/with heparin
- N-FGF-6/1a-IV/without heparin



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 9

